AI Article Synopsis

  • * The cytokine IL-41, initially linked to adipose tissue, has been found to have immunomodulatory properties and was studied for its levels in blood and skin biopsies of SSc patients.
  • * Findings revealed lower levels of IL-41 in patients with diffuse SSc, suggesting it may act as an antifibrotic agent, while elevated levels of a related protein, mTOR, were noted in the skin of these patients.

Article Abstract

Systemic sclerosis (SSc) is an autoimmune connective tissue disease with a triad of features that include vascular abnormalities, inflammation and skin and lung fibrosis. At the core of the disease is the activation of myofibroblasts from quiescent fibroblasts and this can be modified by various cytokines. IL-41 is a recently described cytokine that was initially characterised as an adipokine as it was highly expressed in adipocytes and adipose tissue. However, it has recently been identified as being widely expressed and has immunomodulatory functions. This study examined the circulating levels of IL-41 and its expression in skin biopsies. We demonstrated significantly reduced levels of IL-41 in diffuse SSc that was also mirrored in the skin of SSc patients. AMPK has been proposed as a downstream target of IL-41, so we also measure mammalian target of rapamycin in skin and found that this is elevated in SSc patients. We speculate that IL-41 maybe an antifibrotic cytokine and its reduction may facilitate the activation of fibroblasts.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11274529PMC
http://dx.doi.org/10.3390/cells13141205DOI Listing

Publication Analysis

Top Keywords

systemic sclerosis
8
levels il-41
8
ssc patients
8
il-41
5
novel cytokine
4
cytokine interleukin-41/meteorin-like
4
interleukin-41/meteorin-like reduced
4
reduced diffuse
4
diffuse systemic
4
sclerosis systemic
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!